Historically, pregnant individuals have been excluded from clinical trials, which has created a significant void in reliable safety data regarding medication use during this critical period. The available evidence suggests that while some medications are deemed safe, comprehensive guidelines are urgently needed to optimize their usage. The painful legacy of the thalidomide scandal serves as a reminder of the potential risks that accompany medication during pregnancy, where choices can impact both maternal and fetal health.
Amid rising concerns about the safety of medications, recent findings illustrate that substance use is notably high among pregnant individuals. A systematic review documented that 56% of this population utilized prescribed medications, with many relying on common drugs like antiemetics, analgesics, and antibiotics. This prevalence is projected to grow further as individuals increasingly bear children later in life, often with pre-existing health conditions requiring pharmacological intervention.
The body of safety data largely stems from observational studies, especially those published in PLOS Medicine. For example, evidence shows no association between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the first trimester and significant congenital malformations. Similarly, recent investigations have found no correlation between first-trimester macrolide antibiotics and major malformations or childhood autoimmune diseases.
Despite the significance of these findings, significant limitations persist. Numerous challenges arise when attempting to draw definitive conclusions from observational studies. One major issue is the risk of confounding by indication—the maternal health conditions being treated often predispose them to worse outcomes regardless of medication use. As noted, maternal health intrinsically influences fetal development; thus, risk assessment must include both treatment benefits and the potential hazards of prescribed drugs.
Furthermore, since neurodevelopmental issues may take years to manifest, long-term studies are critical yet often lacking. Past clinical trials contributed little; recent data reveal that only 1.1% of clinical trial applications from 2019 to 2023 included pregnant participants. Regulatory entities like the US FDA and the European Medicines Agency have modified their guidelines to promote the inclusion of pregnant individuals in clinical research, yet these measures alone cannot bridge the evidence gap.
Including pregnant individuals in clinical trials presents several additional complexities. The physiological changes associated with pregnancy can introduce new conditions or complications, necessitating a larger cohort to achieve statistically powered results. Additionally, the traditional trial formats may not adequately address the unique pharmacological needs during pregnancy.
Observational studies remain crucial as they enable the investigation of safety and efficacy efficiently. Utilizing extensive administrative datasets for pharmacovigilance and other study innovations may enhance understanding of medication impacts throughout pregnancy. However, careful modeling of temporal relationships, co-exposures, and maternal health status is essential for accurately interpreting this data. Currently, these insights are predominantly available in higher-income settings, which could raise questions about their relevance in lower-income areas.
To expedite the generation of medication safety data during pregnancy, implementing comprehensive reporting systems is vital. Such systems should consolidate all available information on drugs utilized during pregnancy, including exposure data from trials and natural pregnancies. This effort includes reports from the European Network of Teratology Information Services, which provides clinical guidance and follow-ups on medication exposures.
Utilizing registries to collect data on precise gestational ages and dosages can enable thorough dose-response analyses. Harmonizing data collection methods across different registries and enhancing the linkage between maternal and child health records will improve longitudinal tracking of outcomes that may not surface until years later. Additionally, regulatory changes might necessitate that pharmaceutical companies conduct registry studies for each medication they release, fostering a proactive approach towards safety assessments.
Ultimately, collaborative, systematic strategies are essential for robust analysis across medications used during pregnancy. The editorial team at PLOS Medicine encourages comprehensive studies assessing medication impacts, paired with improved methodologies and reporting standards. This endeavor will help minimize uncertainty around medication safety during pregnancy, ameliorating maternal and fetal health while addressing public concerns about medication use.
Strengthening the existing evidence base is crucial to allay fears and improve care equity for pregnant individuals and their offspring.